ORBIT Bleeding Risk Score for Atrial Fibrillation

The ORBIT score (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) predicts the risk of major bleeding in patients with atrial fibrillation who are on oral anticoagulation. It's designed to complement stroke-risk tools like CHA2DS2-VASc when weighing the net benefit of anticoagulation — essentially the AF bleeding-risk counterpart to the RIETE and DOAC scores we covered earlier for VTE/AF respectively.

Development

The score was derived and validated by O'Brien et al. (European Heart Journal, 2015) using data from the ORBIT-AF registry, a prospective registry of atrial fibrillation patients across 176 U.S. sites. Of 10,132 patients in the registry, 7,411 were analyzed after excluding those not on oral anticoagulants or lacking follow-up data. Notably, the derivation population included both vitamin K antagonists (warfarin, ~93%) and direct oral anticoagulants (dabigatran, ~7%) — unlike HAS-BLED, which was derived in a warfarin-only population. The score was also validated externally in the ROCKET-AF trial cohort.

Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or bleeding causing a hemoglobin drop ≥2 g/dL or requiring transfusion of ≥2 units of blood.

The Five Components ("ORBIT")

Maximum possible score: 7 points. Notably, anemia and bleeding history are weighted twice as heavily as the other three factors — reflecting that they were the strongest predictors in the derivation cohort. Unlike HAS-BLED, ORBIT does not factor in hypertension, labile INR, or alcohol use, and it doesn't consider which specific anticoagulant a patient is on.

Risk Categories

A more granular point-by-point breakdown has also been published, showing a fairly steady climb in bleeding rate with each additional point (from 1.7/100 patient-years at score 0 up to 14.9/100 patient-years at the maximum score of 7).

Clinical considerations

• A high score is not in itself a reason to withhold anticoagulation; it identifies patients for closer monitoring and modification of reversible bleeding risk factors.

• Other risk factors not part of the ORBIT Score may influence the decision for anticoagulation.

• Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical organ, or bleeding with a hemoglobin drop requiring transfusion of ≥2 units (ISTH criteria).

• ORBIT does not take into account choice of anticoagulant. 

• Clinical judgement and best practice guidelines supersedes adjunct standalone decision tools.

• Risk and benefits of anti-coagulation should be considered in patients, to include shared decsion-making and informed consent, prior to initiating therapy. 

• Consider addressing modifiable risk factors for bleeding.

• Other risk stratification tools to consider include:

  • CHA₂DS₂-VASc Score

  • HAS-BLED

  • ATRIA

Comparative Performance

ORBIT was developed partly because two earlier tools — HAS-BLED and ATRIA — were derived from smaller numbers of bleeding events and showed inconsistent performance across settings. In the original derivation and validation work, ORBIT performed favorably relative to these alternatives. However, subsequent independent validation has been mixed: a study of patients undergoing electrocardioversion (Esteve-Pastor et al., 2016) found ORBIT was not superior to HAS-BLED for predicting major bleeding in that specific population — a reminder that comparative performance can vary by clinical setting.

Guideline Standing

The UK's NICE has specifically recommended ORBIT over other bleeding-risk tools (including HAS-BLED) for AF patients starting or under review for anticoagulation, citing evidence of higher accuracy in predicting absolute bleeding risk — though NICE also notes other tools may still be needed until ORBIT is more fully embedded in clinical systems and electronic health records.

Practical Use

ORBIT is a risk-communication tool, not an automatic anticoagulation switch. A high score should prompt review of modifiable risk factors (blood pressure control, rationalizing unnecessary antiplatelet use, working up anemia) and closer monitoring — rather than reflexively discontinuing anticoagulation, since stroke risk in AF often outweighs bleeding risk even in higher-ORBIT-score patients. As with the other scores in this series, it's intended to inform shared decision-making alongside clinical judgment, not replace it.